Literature DB >> 11839575

Versican is differentially expressed in human melanoma and may play a role in tumor development.

Malika Touab1, Juan Villena, Carlos Barranco, Montserrat Arumí-Uría, Anna Bassols.   

Abstract

Undifferentiated human melanoma cell lines produce a large chondroitin sulfate proteoglycan, different from the well-known melanoma-specific proteoglycan mel-PG (Heredia and colleagues, Arch Biochem Biophys, 333: 198-206, 1996). We have identified this proteoglycan as versican and analyzed the expression of versican in several human melanoma cell lines. Versican isoforms are expressed in undifferentiated cell lines but not in differentiated cells, and the isoform expression pattern depends on the degree of cell differentiation. The V0 and V1 isoforms are found on cells with an early degree of differentiation, whereas the V1 isoform is present in cells with an intermediate degree of differentiation. We have also characterized some functional properties of versican on human melanoma cells: the purified proteoglycan stimulates cell growth and inhibits cell adhesion when cells are grown on fibronectin or collagen type I as substrates, and thus may facilitate tumor cell detachment and proliferation. Furthermore, we have analyzed the expression of versican in human melanocytic nevi and melanoma: 10 benign melanocytic nevi, 10 dysplastic nevi, 11 primary malignant melanomas, and 8 metastatic melanomas were tested. Immunoreactivity for versican was negative in benign melanocytic nevi, weakly to strongly positive in dysplastic nevi, and intensely positive in primary malignant melanomas and metastatic melanomas. Our results indicate that versican is involved in the progression of melanomas and may be a reliable marker for clinical diagnosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11839575      PMCID: PMC1850640          DOI: 10.1016/S0002-9440(10)64874-2

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  39 in total

1.  Proliferative activity in the progression of pigmented skin lesions, diagnostic and prognostic significance.

Authors:  M Korabiowska; U Brinck; P Middel; U Brinkmann; H Berger; H J Radzun; I Ruschenburg; M Droese
Journal:  Anticancer Res       Date:  2000 May-Jun       Impact factor: 2.480

2.  Versican V1 proteolysis in human aorta in vivo occurs at the Glu441-Ala442 bond, a site that is cleaved by recombinant ADAMTS-1 and ADAMTS-4.

Authors:  J D Sandy; J Westling; R D Kenagy; M L Iruela-Arispe; C Verscharen; J C Rodriguez-Mazaneque; D R Zimmermann; J M Lemire; J W Fischer; T N Wight; A W Clowes
Journal:  J Biol Chem       Date:  2001-01-26       Impact factor: 5.157

3.  A modified uronic acid carbazole reaction.

Authors:  T BITTER; H M MUIR
Journal:  Anal Biochem       Date:  1962-10       Impact factor: 3.365

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Identification of the motif in versican G3 domain that plays a dominant-negative effect on astrocytoma cell proliferation through inhibiting versican secretion and binding.

Authors:  Y Wu; Y Zhang; L Cao; L Chen; V Lee; P S Zheng; C Kiani; M E Adams; L C Ang; F Paiwand; B B Yang
Journal:  J Biol Chem       Date:  2001-01-31       Impact factor: 5.157

6.  Versican accumulation in human prostatic fibroblast cultures is enhanced by prostate cancer cell-derived transforming growth factor beta1.

Authors:  A J Sakko; C Ricciardelli; K Mayne; W D Tilley; R G Lebaron; D J Horsfall
Journal:  Cancer Res       Date:  2001-02-01       Impact factor: 12.701

7.  Binding of a large chondroitin sulfate/dermatan sulfate proteoglycan, versican, to L-selectin, P-selectin, and CD44.

Authors:  H Kawashima; M Hirose; J Hirose; D Nagakubo; A H Plaas; M Miyasaka
Journal:  J Biol Chem       Date:  2000-11-10       Impact factor: 5.157

8.  Versican interacts with chemokines and modulates cellular responses.

Authors:  J Hirose; H Kawashima; O Yoshie; K Tashiro; M Miyasaka
Journal:  J Biol Chem       Date:  2000-11-16       Impact factor: 5.157

9.  The proteoglycans aggrecan and Versican form networks with fibulin-2 through their lectin domain binding.

Authors:  A I Olin; M Mörgelin; T Sasaki; R Timpl; D Heinegård; A Aspberg
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

10.  Brain derived versican V2 is a potent inhibitor of axonal growth.

Authors:  M Schmalfeldt; C E Bandtlow; M T Dours-Zimmermann; K H Winterhalter; D R Zimmermann
Journal:  J Cell Sci       Date:  2000-03       Impact factor: 5.285

View more
  46 in total

1.  RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration.

Authors:  Neveen Said; Marta Sanchez-Carbayo; Steven C Smith; Dan Theodorescu
Journal:  J Clin Invest       Date:  2012-03-12       Impact factor: 14.808

Review 2.  Chondroitin sulphate proteoglycans: preventing plasticity or protecting the CNS?

Authors:  K E Rhodes; J W Fawcett
Journal:  J Anat       Date:  2004-01       Impact factor: 2.610

3.  Altered expression of sialylated glycoproteins in breast cancer using hydrazide chemistry and mass spectrometry.

Authors:  Yuan Tian; Francisco J Esteva; Jin Song; Hui Zhang
Journal:  Mol Cell Proteomics       Date:  2012-02-07       Impact factor: 5.911

4.  Age-related differences in human skin proteoglycans.

Authors:  David A Carrino; Anthony Calabro; Aniq B Darr; Maria T Dours-Zimmermann; John D Sandy; Dieter R Zimmermann; J Michael Sorrell; Vincent C Hascall; Arnold I Caplan
Journal:  Glycobiology       Date:  2010-10-14       Impact factor: 4.313

5.  V3 versican isoform alters the behavior of human melanoma cells by interfering with CD44/ErbB-dependent signaling.

Authors:  Daniel Hernández; Laia Miquel-Serra; María-José Docampo; Anna Marco-Ramell; Jennifer Cabrera; Angels Fabra; Anna Bassols
Journal:  J Biol Chem       Date:  2010-11-15       Impact factor: 5.157

6.  Increased expression of versican in the inflammatory response to UVB- and reactive oxygen species-induced skin tumorigenesis.

Authors:  Makoto Kunisada; Flandiana Yogianti; Kunihiko Sakumi; Ryusuke Ono; Yusaku Nakabeppu; Chikako Nishigori
Journal:  Am J Pathol       Date:  2011-10-12       Impact factor: 4.307

7.  Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma.

Authors:  Xiaomu Wei; Todd D Prickett; Cristina G Viloria; Alfredo Molinolo; Jimmy C Lin; Isabel Cardenas-Navia; Pedro Cruz; Steven A Rosenberg; Michael A Davies; Jeffrey E Gershenwald; Carlos López-Otín; Yardena Samuels
Journal:  Mol Cancer Res       Date:  2010-10-13       Impact factor: 5.852

8.  Versican isoform V1 regulates proliferation and migration in high-grade gliomas.

Authors:  Julia Onken; Sylvia Moeckel; Petra Leukel; Verena Leidgens; Fusun Baumann; Ulrich Bogdahn; Arabel Vollmann-Zwerenz; Peter Hau
Journal:  J Neurooncol       Date:  2014-07-27       Impact factor: 4.130

9.  Versican upregulation in Sézary cells alters growth, motility and resistance to chemotherapy.

Authors:  K Fujii; M B Karpova; K Asagoe; O Georgiev; R Dummer; M Urosevic-Maiwald
Journal:  Leukemia       Date:  2015-04-27       Impact factor: 11.528

10.  The accumulation of versican in the nodules of benign prostatic hyperplasia.

Authors:  Lawrence D True; Sarah Hawley; Thomas H Norwood; Kathleen R Braun; Stephen P Evanko; Christina K Chan; Richard C LeBaron; Thomas N Wight
Journal:  Prostate       Date:  2009-02-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.